Study Population
depression, encephalopathy
SECONDARY, ENCEPHALOPATHY
In this preplanned secondary analysis of prospectively collected data from infants enrolled in the HEAL Trial, 500 infants (≥36 weeks’ gestation, with moderate or severe encephalopathy and evidence of perinatal depression, treated with TH) were enrolled and randomized to either TH alone or erythropoietin with TH. Infants were enrolled into the HEAL trial between January 25, 2017, and October 9, 2019, at 17 sites comprising 23 hospitals.